Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes DOI Open Access
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2103 - 2103

Published: Feb. 27, 2025

In recent years, the introduction of sodium-glucose transporter-2 inhibitors (SGLT2is) marked a significant advancement in treatment cardiovascular disease (CVD). Beyond their known effects on glycemic control and lipid profile, SGLT2is demonstrate notable benefits for morbidity mortality, regardless diabetic status. These agents are currently recommended as first-line therapies patients with heart failure, both reduced preserved ejection fraction, they improve symptoms reduce risk hospitalization. While several studies have demonstrated that can incidence major adverse events (MACEs), true impact these atherosclerosis progression myocardial ischemia remains to be fully understood. A global beneficial effect related improved could hypothesized, even though substantial evidence shows direct molecular pathways enhance endothelial function, exhibit anti-inflammatory properties, provide protection. this context, narrative review summarizes current knowledge regarding novel anti-diabetic drugs preventing treating ischemia, aiming define an additional area application beyond failure.

Language: Английский

Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes DOI Open Access
Francesco Piccirillo, Marina Lanciotti, Annunziata Nusca

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(5), P. 2103 - 2103

Published: Feb. 27, 2025

In recent years, the introduction of sodium-glucose transporter-2 inhibitors (SGLT2is) marked a significant advancement in treatment cardiovascular disease (CVD). Beyond their known effects on glycemic control and lipid profile, SGLT2is demonstrate notable benefits for morbidity mortality, regardless diabetic status. These agents are currently recommended as first-line therapies patients with heart failure, both reduced preserved ejection fraction, they improve symptoms reduce risk hospitalization. While several studies have demonstrated that can incidence major adverse events (MACEs), true impact these atherosclerosis progression myocardial ischemia remains to be fully understood. A global beneficial effect related improved could hypothesized, even though substantial evidence shows direct molecular pathways enhance endothelial function, exhibit anti-inflammatory properties, provide protection. this context, narrative review summarizes current knowledge regarding novel anti-diabetic drugs preventing treating ischemia, aiming define an additional area application beyond failure.

Language: Английский

Citations

0